HCV: antiviral therapy tied to lower risk for parkinsonism

  • Su TH & al.
  • Mov Disord
  • 10 Sep 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • HCV is associated with an increased risk for parkinsonism that is attenuated by antiviral treatment.  

Why this matters

  • Findings add to mounting evidence of a link between HCV and Parkinson’s disease.

    Key results

    • Parkinsonism incidence was higher among patients with HCV vs control patients (492 vs 403 per 100,000 person-years; P<.0001>
    • HCV was tied to increased risks for (all P<.001 style="list-style-type:circle;">
    • Parkinsonism (aHR=1.306);
    • Requiring anti-Parkinson medication (aHR=1.323); and
    • Parkinson’s disease (aHR=1.203).
  • Parkinsonism risk remained elevated after excluding patients diagnosed within 1 year (aHR=1.367; P<.001 or years p of hcv diagnosis.>
  • In HCV subanalysis, incidence of parkinsonism was lower among treated patients (153 vs 253 per 100,000 person-years; P<.0001>
  • HCV antivirals were associated with lower risk for (all P<.001 style="list-style-type:circle;">
  • Parkinsonism (aHR=0.618);
  • Requiring anti-Parkinson medication (aHR=0.651); and
  • Parkinson’s disease (aHR=0.589).
  • Parkinsonism risk remained lower after excluding patients in the first year (aHR=0.654; P<.001>
  • Extensive sensitivity analyses confirmed findings.
  • Study design

    • Case-control study of 49,342 HCV-infected patients propensity-matched 1:1 with non-HCV ‘controls’ from the Taiwanese National Health Insurance Research Database (2004-2012).
    • HCV subanalysis: 23,647 patients receiving ≥24 weeks of peginterferon-ribavirin were matched 1:1 with untreated patients.
    • Funding: Taiwan Ministry of Science and Technology, Liver Disease Prevention & Treatment Research Foundation of Taiwan, other institutions.

    Limitations

    • Observational design based on claims data.

    Please confirm your acceptance

    To gain full access to GPnotebook please confirm:

    By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

    Submit